Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

HER2-positive Breast Cancer 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Electronic Health Records × Clear all
NCT05769751 2023-08-16

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

Daiichi Sankyo

Completed
865 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡